Advertisement

In Situ Hybridization Analysis of Long Non-coding RNAs MALAT1 and HOTAIR in Gastroenteropancreatic Neuroendocrine Neoplasms

  • Ying-Hsia Chu
  • Heather Hardin
  • Jens Eickhoff
  • Ricardo V. LloydEmail author
Article

Abstract

Recent studies suggest onco-regulatory roles for two long non-coding RNAs (lncRNAs), MALAT1 and HOTAIR, in various malignancies; however, these lncRNAs have not been previously examined in neuroendocrine neoplasms (NENs) of gastroenteropancreatic origins (GEP-NENs). In this study, we evaluated the expressions and prognostic significance of MALAT1 and HOTAIR in 83 cases of GEP-NENs (60 grade 1, 17 grade 2, and 6 grade 3 tumors) diagnosed during the years 2005–2017. Expression levels of MALAT1 and HOTAIR were digitally quantitated in assembled tissue microarray slides labeled by chromogenic in situ hybridization (ISH) using InForm 1.4.0 software. We found diffuse nuclear expression of both HOTAIR and MALAT1 in all primary tumors of GEP-NENs with variable intensities. By multivariate model which adjusted for age and histologic grade, high expression of HOTAIR was associated with lower presenting T and M stages and subsequent development of metastases (P < 0.05). MALAT1 expression was associated with presenting T stage and development of metastases (P < 0.05). In summary, MALAT1 and HOTAIR are commonly expressed in GEP-NENs. High expression of either lncRNA showed grade-independent associations with clinically less aggressive disease.

Keywords

HOTAIR MALAT1 Gastroenteropancreatic neuroendocrine neoplasms siRNA Proliferation Invasion 

Notes

Acknowledgements

The authors thank the University of Wisconsin Translational Research Initiatives in Pathology Laboratory, in part supported by the University of Wisconsin Department of Pathology and Laboratory Medicine and University of Wisconsin Carbone Cancer Center grant P30 CA014520, for use of its facilities and services.

Dr. Chu and Dr. Lloyd received a Research and Development Award from the Department of Pathology and Laboratory Medicine, University of Wisconsin Hospital and Clinics to conduct the study.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that there are no conflicts of interest.

References

  1. 1.
    Ohike N, Adsay NV, La Rosa S, Volante M, Zamboni G. 2017. WHO Classification of Tumours of Endocrine Organs, 10 ed. WHO Press, World Health Organization, Geneva.Google Scholar
  2. 2.
    Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. 2016. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist 21:1191–1199.CrossRefGoogle Scholar
  3. 3.
    Oberg K. 2009. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes 16:72–78.CrossRefGoogle Scholar
  4. 4.
    Lewis MA, Yao JC. 2014. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Current Opinion in Endocrinology, Diabetes and Obesity 21:22–27.CrossRefGoogle Scholar
  5. 5.
    Amair-Pinedo F, Matos I, Sauri T, Hernando J, Capdevila J. 2017. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Target Oncol 12:757–774.CrossRefGoogle Scholar
  6. 6.
    Thorns C, Schurmann C, Gebauer N, et al. 2014. Global microRNA profiling of pancreatic neuroendocrine neoplasias. Anticancer Res 34:2249–2254.PubMedGoogle Scholar
  7. 7.
    Malczewska A, Kidd M, Matar S, Kos-Kudla B, Modlin IM. 2018. A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology 107:73–90.CrossRefGoogle Scholar
  8. 8.
    Yoon JH, Abdelmohsen K, Gorospe M. 2013. Posttranscriptional gene regulation by long noncoding RNA. J Mol Biol 425:3723–3730.CrossRefGoogle Scholar
  9. 9.
    Rinn JL, Chang HY. 2012. Genome regulation by long noncoding RNAs. Annu Rev Biochem 81:145–166.CrossRefGoogle Scholar
  10. 10.
    Yang Y, Junjie P, Sanjun C, Ma Y. 2017. Long non-coding RNAs in Colorectal Cancer: Progression and Future Directions. J Cancer 8:3212–3225.CrossRefGoogle Scholar
  11. 11.
    Modali SD, Parekh VI, Kebebew E, Agarwal SK. 2015. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol 29:224–237.CrossRefGoogle Scholar
  12. 12.
    Parekh VI, Modali SD, Desai SS, Agarwal SK. 2015. Consequence of Menin Deficiency in Mouse Adipocytes Derived by In Vitro Differentiation. Int J Endocrinol 2015:149826.CrossRefGoogle Scholar
  13. 13.
    Wei YL, Hua J, Liu XY, Hua XM, Sun C, Bai JA, Tang QY 2018. LncNEN885 inhibits epithelial-mesenchymal transition by partially regulation of Wnt/beta-catenin signalling in gastroenteropancreatic neuroendocrine neoplasms. Cancer Sci 109:3139–3148.CrossRefGoogle Scholar
  14. 14.
    Pang EJ, Yang R, Fu XB, Liu YF. 2015. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumour Biol 36:2403–2407.CrossRefGoogle Scholar
  15. 15.
    Zheng HT, Shi DB, Wang YW, Li XX, Xu Y, Tripathi P, Gu WL, Cai GX, Cai SJ 2014. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol 7:3174–3181.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Wu ZH, Wang XL, Tang HM, et al. 2014. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol Rep 32:395–402.CrossRefGoogle Scholar
  17. 17.
    Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, Kim S, Safe S 2013. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 32:1616–1625.CrossRefGoogle Scholar
  18. 18.
    Emadi-Andani E, Nikpour P, Emadi-Baygi M, Bidmeshkipour A. 2014. Association of HOTAIR expression in gastric carcinoma with invasion and distant metastasis. Adv Biomed Res 3:135.CrossRefGoogle Scholar
  19. 19.
    Ge XS, Ma HJ, Zheng XH, Ruan HL, Liao XY, Xue WQ, Chen YB, Zhang Y, Jia WH 2013. HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF-1 expression and activates Wnt pathway. Cancer Sci 104:1675–1682.CrossRefGoogle Scholar
  20. 20.
    Kwok ZH, Roche V, Chew XH, Fadieieva A, Tay Y. 2018. A non-canonical tumor suppressive role for the long non-coding RNA MALAT1 in colon and breast cancers. Int J Cancer  https://doi.org/10.1002/ijc.31386, 143, 668, 678.CrossRefPubMedGoogle Scholar
  21. 21.
    Han Y, Wu Z, Wu T, Huang Y., Cheng Z., Li X., Sun T., Xie X., Zhou Y., du Z. 2016. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling. Cell Death Dis 7:e2123.CrossRefGoogle Scholar
  22. 22.
    Cao S, Wang Y, Li J, Lv M, Niu H, Tian Y. 2016. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and activating FBXW7 function. Am J Cancer Res 6:2561–2574.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN, Lee H, Zhou Z, Gan B, Nakagawa S, Ellis MJ, Liang H, Hung MC, You MJ, Sun Y, Ma L 2018. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet 50:1705–1715.CrossRefGoogle Scholar
  24. 24.
    Zhao M, Wang S, Li Q, Ji Q, Guo P, Liu X. 2018. MALAT1: A long non-coding RNA highly associated with human cancers. Oncol Lett 16:19–26.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Hajjari M, Salavaty A. 2015. HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer Biol Med 12:1–9.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Hirata H, Hinoda Y, Shahryari V, Deng G., Nakajima K., Tabatabai Z.L., Ishii N., Dahiya R. 2015. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. Cancer Res 75:1322–1331.CrossRefGoogle Scholar
  27. 27.
    Zhang R, Hardin H, Huang W, Chen J, Asioli S, Righi A, Maletta F, Sapino A, Lloyd RV 2017. MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR. Endocr Pathol 28:7–12.CrossRefGoogle Scholar
  28. 28.
    Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P 2018. MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol 11:63.CrossRefGoogle Scholar
  29. 29.
    Tang Q, Hann SS. 2018. HOTAIR: An Oncogenic Long Non-Coding RNA in Human Cancer. Cell Physiol Biochem 47:893–913.CrossRefGoogle Scholar
  30. 30.
    Ji S, Qin Y, Shi S, Liu X., Hu H., Zhou H., Gao J., Zhang B., Xu W., Liu J., Liang D., Liu L., Liu C., Long J., Zhou H., Chiao P.J., Xu J., Ni Q., Gao D., Yu X. 2015. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res 25:561–573.CrossRefGoogle Scholar
  31. 31.
    Chang YT, Lin TP, Tang JT, Campbell M, Luo YL, Lu SY, Yang CP, Cheng TY, Chang CH, Liu TT, Lin CH, Kung HJ, Pan CC, Chang PC 2018. HOTAIR is a REST-regulated lncRNA that promotes neuroendocrine differentiation in castration resistant prostate cancer. Cancer Lett 433:43–52.CrossRefGoogle Scholar
  32. 32.
    Chakravadhanula M, Ozols VV, Hampton CN, Zhou L, Catchpoole D, Bhardwaj RD. 2014. Expression of the HOX genes and HOTAIR in atypical teratoid rhabdoid tumors and other pediatric brain tumors. Cancer Genet 207:425–428.CrossRefGoogle Scholar
  33. 33.
    Zhang R, Hardin H, Huang W, Buehler D, Lloyd RV. 2018. Long Non-coding RNA Linc-ROR Is Upregulated in Papillary Thyroid Carcinoma. Endocr Pathol 29:1–8.CrossRefGoogle Scholar
  34. 34.
    Hardin H, Helein H, Meyer K, Robertson S, Zhang R, Zhong W, Lloyd RV 2018. Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of lncRNAs. Lab Invest 98:1133–1142.CrossRefGoogle Scholar
  35. 35.
    Vijayvergia N, Boland PM, Handorf E, Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ, Engstrom PF 2016. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. Br J Cancer 115:564–570.CrossRefGoogle Scholar
  36. 36.
    Kim ST, Lee SJ, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS 2016. Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. J Cancer 7:1044–1048.CrossRefGoogle Scholar
  37. 37.
    Kyriakopoulos G, Mavroeidi V, Chatzellis E, Kaltsas GA, Alexandraki KI. 2018. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Ann Transl Med 6:252.CrossRefGoogle Scholar
  38. 38.
    Yadav R, Kakkar A, Sharma A, Malik PS, Sharma MC. 2016. Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors. Scand J Gastroenterol 51:994–999.CrossRefGoogle Scholar
  39. 39.
    Mukhopadhyay S, Dermawan JK, Lanigan CP, Farver CF. 2018. Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. Mod Pathol  https://doi.org/10.1038/s41379-018-0122-7.
  40. 40.
    Lilo MT, Chen Y, LeBlanc RE. 2018. INSM1 is More Sensitive and Interpretable than Conventional Immunohistochemical Stains Used to Diagnose Merkel Cell Carcinoma. Am J Surg Pathol  https://doi.org/10.1097/pas.0000000000001136, 42, 1541, 1548.CrossRefPubMedGoogle Scholar
  41. 41.
    Rosenbaum JN, Guo Z, Baus RM, Werner H, Rehrauer WM, Lloyd RV. 2015. INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms. Am J Clin Pathol 144:579–591.CrossRefGoogle Scholar
  42. 42.
    Tanigawa M, Nakayama M, Taira T, Hattori S, Mihara Y, Kondo R, Kusano H, Nakamura K, Abe Y, Ishida Y, Okabe Y, Hisaka T, Okuda K, Fujino K, Ito T, Kawahara A, Naito Y, Yamaguchi R, Akiba J, Akagi Y, Yano H 2018. Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor. Med Mol Morphol 51:32–40.CrossRefGoogle Scholar
  43. 43.
    Rooper LM, Bishop JA, Westra WH. 2018. INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors. Am J Surg Pathol 42:665–671.CrossRefGoogle Scholar
  44. 44.
    Xin Z, Zhang Y, Jiang Z, Zhao L, Fan L, Wang Y, Xie S, Shangguan X, Zhu Y, Pan J, Liu Q, Huang Y, Dong B, Xue W 2018. Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. Hum Pathol 79:151–159.CrossRefGoogle Scholar
  45. 45.
    Uri I, Grozinsky-Glasberg S. 2018. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol 4:16.CrossRefGoogle Scholar
  46. 46.
    Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. 2010. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 139:742–753, 753.e741CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Ying-Hsia Chu
    • 1
  • Heather Hardin
    • 1
  • Jens Eickhoff
    • 2
  • Ricardo V. Lloyd
    • 1
  1. 1.Department of Pathology and Laboratory MedicineUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA
  2. 2.Department of Biostatistics and Medical InformaticsUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA

Personalised recommendations